S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as S-1, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal
antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. Giving S-1 together with bevacizumab may kill more
tumor cells.
PURPOSE: This phase II trial is studying how well giving S-1 together with bevacizumab works
as third-line therapy in treating patients with colorectal cancer that is recurrent or that
cannot be removed by surgery.